Therapeutic Effects of Citral Nanoliposome on Parkinson’s Treatment in a Rat Model: Modulation via Neurochemical, Inflammatory and Antioxidant Pathways

IF 0.5 4区医学 Q4 NEUROSCIENCES

Neurochemical Journal Pub Date : 2024-05-27 DOI:10.1134/s1819712424020090

Roya Malekloo, Khashayar Bahramsari, Elham Sadat Afraz, Razieh Hassanzadeh, Asal Safarbalou, Ali Mohammad Falahati, Saeid Abbasi-Maleki, Ilia Asadi, Nasrollah Moradikor

{"title":"Therapeutic Effects of Citral Nanoliposome on Parkinson’s Treatment in a Rat Model: Modulation via Neurochemical, Inflammatory and Antioxidant Pathways","authors":"Roya Malekloo, Khashayar Bahramsari, Elham Sadat Afraz, Razieh Hassanzadeh, Asal Safarbalou, Ali Mohammad Falahati, Saeid Abbasi-Maleki, Ilia Asadi, Nasrollah Moradikor","doi":"10.1134/s1819712424020090","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Abstract</h3><p>Parkinson’s disease is the most common neurodegenerative movement disorder, the pathogenesis of which is partly related with oxidant status and inflammatory responses. The administration of citral with antioxidant and anti-inflammatory properties may alleviate the negative effects of Parkinson. The present study aimed to assess the effects of citral nanoliposome on Parkinson’s treatment in a rat model. In this study, citral nanoliposome was successfully produced through employing a facile method. Additionally, 40 Wistar rats were divided into four groups (<i>n</i> = 10), one of which was considered as Sham and received no treatment. However, the other groups were administrated with rotenone, and/or treated with 5 and 10 mg/kg of citral for 21 days. Behavioral responses were evaluated based on the forced swimming test and hippocampal-dependent memory deficit. The rates were examined for tissue lipid peroxide (LPO), as well as the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in brain. Further, they were investigated in terms of expression of brain-derived neurotrophic factor (BDNF), tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and nuclear factor kappa B (NF-κB). The results suggested more immobility, higher LPO level, and a rise in the expression of TNF-α, IL-6, and NF-κB (<i>P</i> = 0.001) following rotenone administration. Furthermore, this treatment decreased climbing, retention latency, SOD and GPx activities, and BDNF expression (<i>P</i> = 0.001). The use of citral, especially in higher dose, reversed all the adverse effects of rotenone on behavioral responses, antioxidant status, BDNF, and inflammatory genes. Parkinson represents a closed relationship with movement deficiency, increased inflammation, and reduced oxidant status. Citral administration can be considered as a therapeutic option following future studies.</p>","PeriodicalId":19119,"journal":{"name":"Neurochemical Journal","volume":"62 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurochemical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1134/s1819712424020090","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Parkinson’s disease is the most common neurodegenerative movement disorder, the pathogenesis of which is partly related with oxidant status and inflammatory responses. The administration of citral with antioxidant and anti-inflammatory properties may alleviate the negative effects of Parkinson. The present study aimed to assess the effects of citral nanoliposome on Parkinson’s treatment in a rat model. In this study, citral nanoliposome was successfully produced through employing a facile method. Additionally, 40 Wistar rats were divided into four groups (n = 10), one of which was considered as Sham and received no treatment. However, the other groups were administrated with rotenone, and/or treated with 5 and 10 mg/kg of citral for 21 days. Behavioral responses were evaluated based on the forced swimming test and hippocampal-dependent memory deficit. The rates were examined for tissue lipid peroxide (LPO), as well as the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in brain. Further, they were investigated in terms of expression of brain-derived neurotrophic factor (BDNF), tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and nuclear factor kappa B (NF-κB). The results suggested more immobility, higher LPO level, and a rise in the expression of TNF-α, IL-6, and NF-κB (P = 0.001) following rotenone administration. Furthermore, this treatment decreased climbing, retention latency, SOD and GPx activities, and BDNF expression (P = 0.001). The use of citral, especially in higher dose, reversed all the adverse effects of rotenone on behavioral responses, antioxidant status, BDNF, and inflammatory genes. Parkinson represents a closed relationship with movement deficiency, increased inflammation, and reduced oxidant status. Citral administration can be considered as a therapeutic option following future studies.

Abstract Image

查看原文本刊更多论文

柠檬醛纳米脂质体对帕金森病大鼠模型的治疗效果：通过神经化学、炎症和抗氧化途径进行调节

摘要帕金森病是最常见的神经退行性运动障碍，其发病机制部分与氧化状态和炎症反应有关。服用具有抗氧化和抗炎特性的柠檬醛可减轻帕金森的负面影响。本研究旨在评估柠檬醛纳米脂质体对帕金森大鼠模型的治疗效果。本研究采用简便的方法成功制备了柠檬醛纳米脂质体。此外，40 只 Wistar 大鼠被分为四组（n = 10），其中一组被视为 Sham 组，不接受任何治疗。其他各组则使用鱼藤酮和/或 5 毫克/千克和 10 毫克/千克的柠檬醛治疗 21 天。行为反应根据强迫游泳测试和海马依赖性记忆缺失进行评估。检测了组织过氧化脂质（LPO）的比率以及大脑中超氧化物歧化酶（SOD）和谷胱甘肽过氧化物酶（GPx）的活性。此外，还研究了脑源性神经营养因子（BDNF）、肿瘤坏死因子（TNF-α）、白细胞介素-6（IL-6）和核因子卡巴B（NF-κB）的表达情况。结果表明，使用鱼藤酮后，动物的活动能力增强，LPO水平升高，TNF-α、IL-6和NF-κB的表达量增加（P = 0.001）。此外，这种治疗方法还能减少爬行、滞留潜伏期、SOD 和 GPx 活性以及 BDNF 的表达（P = 0.001）。柠檬醛的使用，尤其是高剂量的使用，逆转了鱼藤酮对行为反应、抗氧化状态、BDNF 和炎症基因的所有不良影响。帕金森与运动障碍、炎症加重和氧化状态降低之间存在着一种封闭的关系。在今后的研究中，可以考虑将服用柠檬醛作为一种治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurochemical Journal 医学-神经科学

自引率

20.00%

发文量

审稿时长

>12 weeks

期刊介绍： Neurochemical Journal (Neirokhimiya) provides a source for the communication of the latest findings in all areas of contemporary neurochemistry and other fields of relevance (including molecular biology, biochemistry, physiology, neuroimmunology, pharmacology) in an afford to expand our understanding of the functions of the nervous system. The journal presents papers on functional neurochemistry, nervous system receptors, neurotransmitters, myelin, chromaffin granules and other components of the nervous system, as well as neurophysiological and clinical aspects, behavioral reactions, etc. Relevant topics include structure and function of the nervous system proteins, neuropeptides, nucleic acids, nucleotides, lipids, and other biologically active components. The journal is devoted to the rapid publication of regular papers containing the results of original research, reviews highlighting major developments in neurochemistry, short communications, new experimental studies that use neurochemical methodology, descriptions of new methods of value for neurochemistry, theoretical material suggesting novel principles and approaches to neurochemical problems, presentations of new hypotheses and significant findings, discussions, chronicles of congresses, meetings, and conferences with short presentations of the most sensational and timely reports, information on the activity of the Russian and International Neurochemical Societies, as well as advertisements of reagents and equipment.